$0.79
+0.02 (+1.98%)
Open$0.78
Previous Close$0.77
Day High$0.80
Day Low$0.77
52W High$4.47
52W Low$0.65
Volume—
Avg Volume66.9K
Market Cap6.21M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,471.3% upside
Current
$0.79
$0.79
Target
$12.39
$12.39
$9.33
$12.39 avg
$15.15
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.16M | 3.05M | 3.43M |
| Net Income | -41,291 | -50,098 | -44,694 |
| Profit Margin | -1.3% | -1.6% | -1.3% |
| EBITDA | -71,807 | -61,818 | -76,890 |
| Free Cash Flow | -34,920 | -36,621 | -42,296 |
| Rev Growth | +21.0% | -5.0% | +24.8% |
| Debt/Equity | 0.35 | 0.39 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |